Filing Flows › Twist Bioscience (TWST) › Q2 FY25
Twist Bioscience (TWST) Q2 FY25 earnings results (second quarter fiscal 2025)
10-Q filed May 5, 2025
Twist Bioscience (TWST) reported revenue of $92.8M for the second quarter fiscal 2025 (Q2 FY25), +23% from a year earlier and +5% from the quarter before. Operating margin was -44.8%, net loss $39.3M (42.4% of revenue).
Twist Bioscience, Q2 FY25: revenue $92.8M (+23% year over year), operating margin -44.8%, net loss $39.3M, operating cash flow −$13.0M. The chart follows the revenue to costs, profit and cash.
| Q2 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $92.8M | +5% | +23% |
| Operating profit | −$41.6M | — | — |
| Net earnings | −$39.3M | — | — |
| Operating cash flow | −$13.0M | — | — |
What changed
Revenue was $92.8M in Q2 FY25, up 23% year over year and up 5% from the previous quarter. NGS tools was the largest line at 55% of revenue. NGS tools added $10.4M year over year (up 25%), 59% of the total change. DNA libraries declined 15%.
Operating costs exceeded revenue by $41.6M, an operating margin of -44.8%. Total costs grew 8% against revenue growth of 23%. The fastest-growing cost line was SG&A (+14%). The quarter ended with a net loss of $39.3M, wider than the previous quarter's $31.6M loss.
Operating cash flow was −$13.0M. Non-cash charges added back $6.4M of depreciation and amortization and $20.3M of share-based compensation. Capital expenditures of $4.1M exceeded it, leaving free cash flow of −$17.1M.
Questions
What was Twist Bioscience's revenue in the second quarter fiscal 2025?
Twist Bioscience (TWST) reported revenue of $92.8M for the second quarter fiscal 2025 (Q2 FY25), +23% from a year earlier and +5% from the quarter before.
Was Twist Bioscience profitable in the second quarter fiscal 2025?
Operating loss was $41.6M (-44.8% of revenue) and net loss $39.3M.
Source: Twist Bioscience 10-Q on SEC EDGAR.